Safety and pharmacokinetics of repeat-dose micafungin in young infants. - Wikidata - wikimedia - TriplyDB

Safety and pharmacokinetics of repeat-dose micafungin in young infants.

Safety and pharmacokinetics of repeat-dose micafungin in young infants.

http://www.wikidata.org/entity/Q30433612

about

Innovative clinical trial design for pediatric therapeutics Treatment and prophylaxis of invasive candidiasis Management strategies in the treatment of neonatal and pediatric gastroenteritis Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications Changes in the incidence of candidiasis in neonatal intensive care units.Prediction of micafungin area under the curve data by using peak concentration: applicability and utility in antifungal therapy.Micafungin use in children.Population pharmacokinetics of micafungin in neonates and young infants Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Neonatal infectious diseases: evaluation of neonatal sepsis.Micafungin in premature and non-premature infants: a systematic review of 9 clinical trials.Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.Dosing in neonates: special considerations in physiology and trial design.Population pharmacokinetics of micafungin and its metabolites M1 and M5 in children and adolescents.Safety and Effectiveness of Micafungin in Japanese Pediatric Patients: Results of a Postmarketing Surveillance Study.Commentary: pediatric antifungal drug development: lessons learned and recommendations for the future.Pharmacokinetics of micafungin in subjects with severe hepatic dysfunction.Intermittent Dosing of Micafungin Is Effective for Treatment of Experimental Disseminated Candidiasis in Persistently Neutropenic Rabbits.Neonatal Candidiasis: New Insights into an Old Problem at a Unique Host-Pathogen Interface Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazole Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective.Optimizing operational efficiencies in early phase trials: The Pediatric Trials Network experience.Role of echinocandins in the management of fungal infections in neonates.Safety of micafungin in infants: insights into optimal dosing.The management of Candida infections in preterm neonates and the role of micafungin.Fungal infections in pediatric intensive care units.Echinocandin use in the neonatal intensive care unit.Invasive fungal infections during the neonatal period: diagnosis, treatment and prophylaxis.The use of antifungal therapy in neonatal intensive care.Invasive fungal infections in newborns and current management strategies.Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants.Impact of special patient populations on the pharmacokinetics of echinocandins.Pharmacokinetic considerations in treating invasive pediatric fungal infections.Pharmacokinetics and Safety of Micafungin in Infants Supported With Extracorporeal Membrane Oxygenation.Clinical Pharmacokinetics and Pharmacodynamics of Micafungin.Pharmacokinetics of micafungin in HIV positive patients with confirmed esophageal candidiasis.Development of New Strategies for Echinocandins: Progress in Translational Research.Pharmacokinetics and safety of fluconazole and micafungin in neonates with systemic candidiasis: a randomized open-label clinical trial.A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants with Invasive Candidiasis.

P2860

Q24635308-E4DFCB00-E7A9-4708-9C27-1D82572A5FDF Q27001567-9C3BBB51-094F-40B9-B0E5-1071F727A7E4 Q27004496-87C2BEB0-9CFA-49C4-B7DA-B59475010C59 Q27025299-66B14779-269F-41D8-96C3-B156E1BB9172 Q30408409-3387D8B0-77BF-4083-91AC-D90C49ED1293 Q31075176-ED5A2612-26E7-4B6B-A62A-345B64F44B6D Q33397111-347E4667-8C66-48E8-AEBC-C00905D860AA Q33876608-BC862D11-35D5-4BC1-91D8-D5CFB241AFE0 Q34212799-AC0C6905-B1D7-4025-B173-48B66F8FF35A Q34332344-0B29A08D-96E7-4D3E-A1E8-06ACABB4F62D Q34337608-E794AD43-31B4-4474-9FA8-71003DE65A35 Q34505582-344629CF-058F-44FB-9D22-C29FAD63ABF1 Q34716879-0770375D-B580-48E3-B392-CADA31823B96 Q35105985-92351127-B849-4F5A-8C7D-C372D0D313ED Q35787372-77C289F2-F633-4B16-A410-850DD754CE07 Q35973357-57272B69-D444-4219-BB9F-D4D53C88A9D8 Q36004967-750FDD8C-EAB6-479D-A421-DED5099BD938 Q36276191-A3F95051-9B3B-4098-94FE-9E8D23FAA184 Q36462048-BF8675C2-A4BF-4AE9-8D40-FA1105F20324 Q36521993-1CC406E1-A97F-4F39-BA27-379F234330A4 Q36948094-2D061C93-1659-4FC3-A60A-13B71255FA31 Q37203671-CE160242-2E4E-4322-BB11-FC7A82DCE666 Q37790698-E96FAB37-CE2E-4031-83F9-090DDEC1D8ED Q37827883-0F4644E5-6EBA-48C7-862C-3C340FA90CC1 Q37900293-DFCB8B0D-1856-4EB3-B9CE-7806DA32E545 Q37900308-295CC617-12E3-4206-9B02-AE2FE810BD04 Q37970649-FA137588-F264-4F86-912B-6CE5ED2B5859 Q37973390-42ACC2CC-D6C5-458C-8EA3-1DD494CA80FF Q37985070-28BB4B63-2A25-4AF9-AED2-6205DB36A5DC Q38119554-4635E986-72FB-4975-9685-207632748559 Q38193337-7F370FB5-2B3B-486E-9122-A6EF7DC1C1D1 Q38215682-25A404AC-CF05-4D46-BE99-632A25F3B8A4 Q38462784-FD196C7E-9299-43F7-B55A-4E03462B6212 Q38816614-6BAD8608-5CE9-4800-B05F-94A8D733E9CC Q39675383-197EE9B5-E71E-42D2-A643-21437E9D789A Q40100873-962C6AAB-0D23-4798-A65C-F44CA740E47F Q44685491-80117FF1-048C-40C3-8A03-74294A12FEBF Q46639635-F59DEA1C-E05A-40A7-84E9-B238AB7C6893 Q53823442-385D8525-6980-4DBF-B041-3A6A7D0D4015 Q53834039-BFFA4593-6095-4E38-9F63-B4FB6D68D715

P2860

Safety and pharmacokinetics of repeat-dose micafungin in young infants.

http://www.wikidata.org/entity/Q30433612

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Safety and pharmacokinetics of repeat-dose micafungin in young infants.

@ast

Safety and pharmacokinetics of repeat-dose micafungin in young infants.

@en

type

label

Safety and pharmacokinetics of repeat-dose micafungin in young infants.

@ast

Safety and pharmacokinetics of repeat-dose micafungin in young infants.

@en

prefLabel

Safety and pharmacokinetics of repeat-dose micafungin in young infants.

@ast

Safety and pharmacokinetics of repeat-dose micafungin in young infants.

@en

P1433

Q30433612-0725E121-85B8-4F48-950E-1B959F96C4CE

P1476

Q30433612-323110F8-DC48-401C-9A5D-DC582F5EB5EA

P2093

Q30433612-00CB4C14-4D69-4A95-A1E8-B21E4F841066

Q30433612-23572ED5-DAAA-4499-A728-E1ED72CA1882

Q30433612-499E1BDC-4765-49C0-A661-FFEFFA222133

Q30433612-4BFAF51D-DC68-46D8-BB35-CCD4252013CF

Q30433612-6440F2EE-75F0-476A-B72E-C96658253C65

Q30433612-6871BB9F-C4C1-4BB1-9FD3-EF163351A9CD

Q30433612-97A7C14C-11AB-4AC0-A310-C19BF02601E2

Q30433612-ADDAE604-1E42-45A1-841B-748834ED14DC

Q30433612-DA2C0854-E842-40CB-B2C0-48CF6E03227C

Q30433612-DE3A5FB4-F021-45CF-80DF-5AF89EA5014D

P2860

Q30433612-18B82C5E-E44E-420E-879A-C3063BDE6087

Q30433612-1B284ECD-4F5F-44B3-8B63-5B72611F2A10

Q30433612-231A7897-87D4-4399-A0EE-9A8367710112

Q30433612-303F990A-3B59-4165-83DE-96DF4CBB231C

Q30433612-35760428-4F72-4B14-9DEA-927AACDEF10E

Q30433612-3A8B994F-C710-476B-8EA0-A5D4CBC8E7DB

Q30433612-3EC38E55-6193-4D1A-9F60-877A776BAE54

Q30433612-43930C48-BFD6-49FD-9BAA-0A81D2F704D9

Q30433612-43B7B6D3-E2B2-4793-9899-07DB4494229D

Q30433612-465C868E-0AB1-472A-A8E2-52D5A6EDDE37

P304

Q30433612-80263995-67D2-4C08-B5B4-299F6F22D4F9

P31

Q30433612-D91E7BF2-E74A-48ED-9904-90B6038F2257

P356

Q30433612-6105156E-5C80-4F6F-BFC4-7B1E9CA44A7A

P407

Q30433612-3E5DB5D3-994E-48CB-8E4F-E656FED71887

P433

Q30433612-E40F7BA2-FF7B-4D53-877E-FEBBB66761EC

P478

Q30433612-F7CBAA2D-B8E3-4510-98C6-300853F20B28

P50

Q30433612-A39827C4-F250-4864-BA15-E53211F696C7

P577

Q30433612-2EE761D5-D1F7-4E55-8AC3-C51C23F11BDC

P5875

Q30433612-9061EB48-D5C6-454E-9344-4230E66B8FD3

P698

Q30433612-4B959D4A-65EC-4E19-BAB4-70E3D17FFA19

P921

Q30433612-1E1D3C27-323E-44A5-ABFC-88D5F4F00270

P932

Q30433612-724EC6D9-0A17-4B5F-B6EA-98D31F115622

P356

P1433

Clinical Pharmacology & Therapeutics

P1476

Safety and pharmacokinetics of repeat-dose micafungin in young infants.

@en

P2093

A Arrieta

http://www.w3.org/2001/XMLSchema#string

D K Benjamin

http://www.w3.org/2001/XMLSchema#string

D Kaufman

http://www.w3.org/2001/XMLSchema#string

D N Buell

http://www.w3.org/2001/XMLSchema#string

L Castro

http://www.w3.org/2001/XMLSchema#string

L J Arnold

http://www.w3.org/2001/XMLSchema#string

L L Kovanda

http://www.w3.org/2001/XMLSchema#string

P B Smith

http://www.w3.org/2001/XMLSchema#string

P J Sánchez

http://www.w3.org/2001/XMLSchema#string

T J Walsh

http://www.w3.org/2001/XMLSchema#string

P2860

Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005

In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi

Fluconazole prophylaxis against fungal colonization and infection in preterm infants.

Pharmacokinetics of an elevated dosage of micafungin in premature neonates.

Empirical therapy for neonatal candidemia in very low birth weight infants.

Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant.

Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients.

Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.

Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits.

In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies

P304

93-99

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/CLPT.2009.200

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

87

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-11-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38067896

http://www.w3.org/2001/XMLSchema#string

P698

19890251

http://www.w3.org/2001/XMLSchema#string

P921

pharmacokinetics

P932

2824925

http://www.w3.org/2001/XMLSchema#string